Glutathione
The body's most abundant antioxidant — a tripeptide critical for detoxification, immune function, and cellular protection, and one of the most widely used systemic skin-brightening and hyperpigmentation interventions via oral, IV, SubQ/IM, and topical routes (note: IV use for skin lightening is FDA-flagged and not approved).
What is Glutathione?
Glutathione is a tripeptide (glutamate-cysteine-glycine) produced naturally in every cell of the body. It is the most abundant intracellular antioxidant and plays critical roles in detoxification, immune function, and protection against oxidative stress. Levels decline with age, stress, and illness. Supplementation is available in oral (including liposomal and S-acetyl), subcutaneous and intramuscular injection, IV infusion, intranasal, and topical forms, with multiple RCTs supporting benefits for skin health, diabetes, immune function, and aging.
What Glutathione Is Investigated For
Glutathione is investigated for antioxidant protection, detoxification, immune support, skin brightening, liver support, and aging applications. The strongest evidence base is mechanistic — glutathione's role as the dominant intracellular thiol antioxidant and Phase II detoxification cofactor is foundational and uncontested — plus multiple RCTs supporting benefits for skin pigmentation, type 2 diabetes/insulin sensitivity, cystic fibrosis, cirrhosis, immune function (tuberculosis, HIV), and the landmark Baylor GlyNAC (glycine + NAC) aging trials showing improvement across multiple aging hallmarks in older adults. Route and form matter enormously: plain oral reduced glutathione has very poor bioavailability, while liposomal, S-acetyl, and precursor strategies (NAC, GlyNAC) reliably raise tissue GSH. The honest caveats are regulatory and cosmetic: IV glutathione for skin lightening — a massive aesthetic industry particularly in Asia — has been flagged by the FDA for unapproved use and adverse-event concerns; it is not FDA-approved for any anti-aging, detoxification, or skin-brightening indication; and the 'detox' framing common in wellness marketing oversells what the molecule actually does in otherwise healthy people. Its cysteine-donating precursor NAC is FDA-approved for acetaminophen toxicity, which remains the clearest therapeutic use case.
History & Discovery
Glutathione was isolated in 1888 by French chemist Joseph de Rey-Pailhade, who observed a reducing substance in brewer's yeast that he called 'philothion.' Its tripeptide structure — gamma-glutamyl-cysteinyl-glycine — was established by Frederick Gowland Hopkins in the 1920s, work that contributed to the broader understanding of amino acid metabolism. By the mid-20th century, glutathione's role as the dominant intracellular thiol antioxidant was well characterized, and its biochemistry has been a core part of redox biology ever since. Clinically, glutathione has a bifurcated history. Its precursor N-acetylcysteine has been FDA-approved since the 1960s and is the standard of care for acetaminophen overdose, where it restores hepatic GSH and prevents liver failure. Glutathione itself has been used intravenously in hospital and compounding settings for decades, with scattered clinical research on Parkinson's disease (Sechi and colleagues in the 1990s; Mischley's group on intranasal GSH more recently), cystic fibrosis, cirrhosis, and chemotherapy-related toxicity. In parallel — and somewhat uncomfortably for the science — glutathione became a major fixture of the aesthetic wellness industry, primarily for skin lightening via IV drip in cosmetic clinics across Asia and increasingly in the US. The FDA issued communications in 2020 and subsequent years flagging concerns about compounded IV glutathione for skin lightening, citing both the lack of approved indication and reports of adverse events; the Philippine FDA and dermatology associations have taken similar positions. The contrast between glutathione's well-grounded biochemistry and the underregulated cosmetic market is one of the most important things to understand about it.
How It Works
Glutathione is your cells' primary defense against damage from toxins and free radicals. It neutralizes harmful molecules, recycles other antioxidants like vitamin C, and helps your liver process and eliminate toxins.
Glutathione functions as the primary intracellular thiol antioxidant. It directly scavenges reactive oxygen species (ROS) and reactive nitrogen species (RNS). As a cofactor for glutathione peroxidase, it reduces hydrogen peroxide and lipid peroxides. Glutathione S-transferases use GSH for Phase II detoxification conjugation reactions. It maintains the reduced forms of vitamins C and E, regenerating their antioxidant capacity. GSH also regulates the nitric oxide cycle, mitochondrial function, and cell proliferation/apoptosis signaling.
Evidence Snapshot
Human Clinical Evidence
Strong. Multiple RCTs for skin lightening, diabetes/insulin sensitivity, cystic fibrosis, cirrhosis, immune function (TB, HIV), autism, acne, and Parkinson's disease. GlyNAC (glycine + NAC) supplementation has landmark RCTs showing improvements in aging hallmarks. Liposomal glutathione RCTs demonstrate immune modulation.
Animal / Preclinical
Extensive. Glutathione biology is fundamental to cellular biochemistry.
Mechanistic Rationale
Very strong. Glutathione's role in redox biology is one of the most well-characterized in biochemistry.
Research Gaps & Open Questions
What the current literature has not yet settled about Glutathione:
- 01Oral bioavailability comparisons — liposomal, S-acetyl, standard reduced GSH, and precursor strategies have not been directly compared in adequately powered head-to-head human trials with tissue-level GSH endpoints.
- 02Long-term IV GSH safety — despite widespread use for skin lightening and wellness, rigorous long-term safety data (beyond case reports of adverse events) is sparse.
- 03Skin lightening mechanism and magnitude — published trials show modest, heterogeneous effects; the mechanism is understood (tyrosinase modulation, eumelanin-to-pheomelanin shift), but durable, well-quantified outcome data is limited.
- 04Parkinson's disease — early intranasal and IV trials have been small and inconsistent. Larger randomized work would clarify whether GSH repletion modifies disease trajectory or only transiently influences symptom scores.
- 05GlyNAC scaling — Baylor's GlyNAC aging trials are promising but small; replication in larger populations and across more diverse cohorts would strengthen the case for precursor-based GSH restoration as an aging intervention.
- 06Cosmetic IV GSH regulation and pharmacovigilance — the scale of off-label use vastly exceeds the reporting infrastructure; a more coherent adverse-event surveillance picture is needed.
Forms & Administration
Oral (liposomal preferred, 250-1000mg/day), subcutaneous or intramuscular injection (200-600mg 1-3x/week, typically from compounding pharmacies), IV infusion (600-2400mg per session), inhaled (nebulized for respiratory applications), intranasal (200-600mg/day in Parkinson's research), topical. S-acetyl glutathione and liposomal forms have improved oral bioavailability.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Oral glutathione: 250–1,000 mg/day of liposomal or S-acetyl formulations (standard reduced GSH has very poor oral bioavailability and is broadly considered less useful in that form). Oral GSH-precursor protocols — most notably GlyNAC (glycine + N-acetylcysteine) — use glycine ~100 mg/kg/day and NAC ~100 mg/kg/day in published RCTs in older adults. Subcutaneous or intramuscular injection: 200–600 mg per shot is the range commonly supplied by compounding pharmacies and self-administered as an alternative to clinic IV, with some aesthetic-market protocols going up to 1,000 mg per injection. IV glutathione: 600–2,400 mg per session is the range described in aesthetic and wellness clinic practice, with Parkinson's trial protocols using similar ranges. Intranasal glutathione in Parkinson's research has used 200–600 mg per day. Topical formulations exist for skin applications but dose-equivalence to systemic routes is not established.
Frequency
Oral liposomal: once or twice daily, typically with food. GlyNAC: split doses with meals given the volume. SubQ/IM injection: typically 1–3x per week, with bodybuilding and skin-lightening protocols sometimes pushing to daily for short cycles. IV: once or twice weekly in most wellness and clinical trial protocols, though aesthetic-market practice varies widely. Intranasal: twice daily per Parkinson's trial protocols.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Continuous daily use is common rather than cycling. Published human trials have run 12 weeks to 16 months without tolerance or cumulative-safety signals at standard doses.
Protocol Notes
Route matters far more for glutathione than for almost any other supplement. Standard reduced glutathione taken as an unmodified oral capsule is extensively broken down by gamma-glutamyltransferase in the intestinal brush border; intact GSH reaching systemic circulation is minimal. This led to the common refrain that 'oral glutathione doesn't work,' which is only half true — liposomal encapsulation, S-acetyl protection, and sublingual delivery meaningfully improve bioavailability, and precursor strategies (NAC, GlyNAC, whey protein) reliably raise tissue GSH by a different mechanism. Subcutaneous and intramuscular glutathione sit between oral and IV. Compounding pharmacies supply preservative-free GSH solutions in multi-dose vials (commonly 200 mg/mL) intended for self-administered SubQ or IM injection, typically into the abdominal fat pad (SubQ) or deltoid/gluteal muscle (IM). A standard 400 mg SubQ dose is 2 mL of a 200 mg/mL preparation. This route gives much higher bioavailability than oral while avoiding the clinic visits and IV access that IV drips require, which is why 'glutathione pushes' and SubQ home-use kits are a growing part of the aesthetic and wellness market. Injection-site reactions (redness, induration, mild bruising) are more common than with IV, and the FDA's compounded-preparation concerns that apply to IV GSH apply to SubQ/IM preparations as well — sterility and source-pharmacy quality are the primary risk variables. IV glutathione bypasses the bioavailability problem but introduces others: compounded sterility risk, the need for IV access and clinical oversight, and — for skin-lightening applications — the specific FDA-flagged concerns about unapproved use of compounded preparations, including adverse event reports involving contamination, hypersensitivity, and thyroid dysfunction. For hospital use as an NAC precursor in acetaminophen toxicity, NAC rather than GSH itself is the approved standard, because NAC is orally and IV-stable and efficiently converted to GSH intrahepatically. Wellness-market use of IV, SubQ, or IM GSH for 'general detoxification' or 'skin lightening' is distinct from this approved therapeutic context and should be evaluated separately.
Glutathione is not FDA-approved for skin lightening, general antioxidant support, or anti-aging indications. FDA has specifically issued concerns about compounded IV glutathione marketed for skin lightening. NAC, its precursor, is approved for acetaminophen toxicity. Aesthetic and wellness use is off-label and should be under qualified clinician oversight.
Timeline of Effects
Onset
IV glutathione produces measurable increases in blood GSH within minutes to hours of infusion. Oral liposomal glutathione raises body GSH stores over 1–4 weeks in trial data. GlyNAC protocols restore GSH-deficient aging phenotypes over 12–24 weeks in the Baylor aging trials. Subjective effects — where users report them — vary widely and are confounded by the indication.
Peak Effect
Sustained-dose protocols typically plateau body GSH at 4–12 weeks. The landmark GlyNAC aging trial followed participants over 16 weeks and found significant improvement in GSH, oxidative stress markers, mitochondrial function, insulin resistance, and multiple aging hallmarks. For skin lightening, multiple trials describe visible effects emerging over 4–12 weeks of consistent use, though effect sizes are modest and heterogeneous.
After Discontinuation
Without continued supplementation or precursor intake, tissue GSH returns toward baseline on a timescale of weeks rather than days. Any benefits that depended on sustained GSH elevation tend to recede accordingly. There is no documented rebound or withdrawal effect.
Common Questions
Who Glutathione Is NOT For
- •Active asthma with sulfite sensitivity — some injectable glutathione preparations contain sulfite preservatives that can trigger bronchospasm in susceptible individuals.
- •Pregnancy and breastfeeding — endogenous glutathione is essential in pregnancy, but supplemental high-dose or IV use has not been studied for maternal and fetal safety; standard guidance is to avoid non-essential supplementation.
- •Known hypersensitivity to glutathione, NAC, or compounded IV preparations or excipients.
- •Organ transplant recipients on immunosuppression — theoretical concerns about modulation of redox-sensitive immune signaling; discuss with transplant team.
- •Active chemotherapy — some chemotherapy agents rely on oxidative mechanisms; glutathione repletion could theoretically oppose them. This is debated in the literature and should be an oncology-led decision.
- •Cosmetic IV GSH for skin lightening — flagged by the FDA as unapproved; this is a regulatory rather than strictly medical contraindication but worth naming separately given the scale of off-label use.
Drug & Supplement Interactions
Most clinically relevant interactions involve glutathione's role in drug metabolism rather than direct pharmacokinetic competition. Chemotherapy: certain agents (cisplatin, doxorubicin, alkylating agents) generate oxidative stress as part of their mechanism of action; high-dose GSH or NAC can theoretically attenuate efficacy. Some oncology protocols explicitly include glutathione to reduce platinum-related neuropathy and renal toxicity; others avoid antioxidants. Decisions should be oncology-led rather than supplement-store-led. Acetaminophen: NAC and glutathione repletion are protective in acute overdose — this is an established therapeutic interaction rather than an adverse one. Anti-angiogenic and anti-inflammatory therapies: no strong documented interaction, though redox modulation could theoretically influence NO-dependent pathways relevant to PDE5 inhibitors, nitrates, and some antihypertensives. Magnitude in practice appears small. Nitroglycerin: long-standing clinical observation that NAC can restore nitroglycerin sensitivity in tolerant patients — not an adverse interaction but a relevant pharmacological consideration. Compounded IV glutathione introduces separate concerns about sterility and contaminant-drug interactions rather than GSH itself — a function of supply chain rather than pharmacology.
Safety Profile
Common Side Effects
Cautions
- • IV glutathione should be administered by healthcare professionals
- • May interact with chemotherapy drugs
- • Quality varies between supplement brands
What We Don't Know
Long-term safety of high-dose IV glutathione is not fully characterized, though the molecule itself is naturally abundant in the body.
Legal Status
United States
Glutathione is sold as a dietary supplement in oral forms. IV glutathione is available only through compounding pharmacies or medical clinics — it is not an FDA-approved drug. In 2020 and in subsequent communications, the FDA flagged specific concerns about compounded IV glutathione marketed for skin lightening, citing lack of approved indication and adverse event reports, though enforcement has been targeted rather than comprehensive. NAC — its cysteine-contributing precursor — is FDA-approved for acetaminophen toxicity and was historically marketed as a supplement; the FDA's position on NAC as a supplement has shifted over the past several years and remains somewhat unsettled.
International
Oral glutathione is broadly available as a supplement in most markets. Compounded IV glutathione for skin lightening is an enormous aesthetic industry in the Philippines, Thailand, other Southeast Asian countries, Japan, and South Korea; multiple national regulators (including the Philippine FDA) have issued advisories about unapproved cosmetic IV GSH. Intranasal glutathione for Parkinson's research is investigational in all jurisdictions.
Sports & Competition
Glutathione and its precursors are not prohibited by WADA. They are not on any major anti-doping prohibited list and are freely usable by competitive athletes, subject to the usual caveat about third-party tested product purity.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
All oral glutathione works equally well.
Reality
Standard reduced glutathione taken as a plain capsule is largely degraded in the GI tract before it reaches the bloodstream. Liposomal encapsulation, S-acetyl protection, and precursor strategies (NAC, GlyNAC, whey) reliably raise tissue GSH; plain oral GSH does so less efficiently. Formulation matters a lot here.
Myth
IV glutathione for skin lightening is FDA-approved.
Reality
It is not. The FDA has specifically communicated concerns about compounded IV glutathione marketed for skin lightening, citing lack of approved indication and adverse event reports. Skin-lightening IV GSH is an off-label, unapproved cosmetic use, regardless of how commonly it is offered.
Myth
Glutathione 'detoxifies' the body of general toxins.
Reality
Glutathione is a real participant in Phase II hepatic conjugation and xenobiotic handling — this is well-established biochemistry. 'Detox' as it is used in wellness marketing, however, often implies a specific, measurable clearance of undefined 'toxins' that GSH does not actually deliver in a clinically meaningful way in otherwise healthy people. The real clinical detoxification use case is acetaminophen toxicity via NAC, which is a different story.
Myth
Glutathione is safe at any dose because it is naturally abundant in the body.
Reality
Endogenous GSH is tightly regulated and compartmentalized. High-dose IV glutathione is a different pharmacological situation than basal endogenous levels, and adverse events — particularly with compounded IV preparations — have been reported. 'Natural' does not substitute for rigorous dose-ranging and safety data.
Myth
NAC and glutathione are interchangeable.
Reality
NAC is a cysteine donor that supports GSH synthesis; it is pharmacokinetically stable, orally bioavailable, and FDA-approved for acetaminophen toxicity. Glutathione itself is a tripeptide with poor standard oral bioavailability and complex route-dependent pharmacology. They overlap in effect but are not the same intervention.
Published Research
50 studiesSodium benzoate treatment linked to increased glutathione levels and improved positive and negative symptoms, global function, and quality of life in patients with clozapine-resistant schizophrenia: secondary analysis of a randomized clinical trial
Efficacy and safety of injectable sodium hyaluronate with vitamin C, tranexamic acid, and glutathione for pigmented dark circles
A randomized, double-blind, placebo-controlled trial of N-acetylcysteine as an adjuvant treatment for alcohol use disorder
Effectiveness of oral glutathione in reducing nitric oxide and IL-1α concentrations for clinical improvement in mild to moderate acne vulgaris: a randomized controlled trial
Multi-omic analysis and platelet function distinguish treatment responses to hydroxytyrosol in cardiovascular risk
Glutathione, Vitamin C, and Cysteine Use in Autistic Children With Disruptive Behavior: A Double-Blind, Placebo-Controlled Crossover Pilot Study
Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients
N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis
Glutathione as a skin-lightening agent and in melasma: a systematic review.
Effects of GSH on Alcohol Metabolism and Hangover Improvement in Humans: A Randomized Double-Blind Placebo-Controlled Crossover Clinical Trial
Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis
Juçara (Euterpe edulis Martius) improves time-to-exhaustion cycling performance and increased reduced glutathione: a randomized, placebo-controlled, crossover, and triple-blind study
Effect of long-term oral glutathione supplementation on gut microbiome of type 2 diabetic individuals
Enhancing Supplemental Effects of Acute Natural Antioxidant Derived from Yeast Fermentation and Vitamin C on Sports Performance in Triathlon Athletes: A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial
Improved glycemic control either alone, or combined with antioxidant supplementation, fails to restore blood glutathione or markers of oxidative stress in adolescents with poorly controlled type 1 diabetes
Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19
The effects of L-Citrulline and Glutathione on Endurance performance in young adult trained males
Combined Citrulline and Glutathione Supplementation Improves Endothelial Function and Blood Pressure Reactivity in Postmenopausal Women
N-acetylcysteine does not alter neurometabolite levels in non-treatment seeking adolescents who use alcohol heavily: A preliminary randomized clinical trial
Eight-week supplementation of Aronia berry extract promoted the glutathione defence system against acute aerobic exercise-induced oxidative load immediately and 30 min post-exercise in healthy adults: a double-blind, randomised controlled trial
Reduction of lead toxicity effects and enhancing the glutathione reservoir in green beans through spraying sulfur and serine and glutamine amino acids
Early and prolonged glutathione infusion favorably impacts length of hospital stay in ST-elevation myocardial infarction patients: a subanalysis of the GSH2014 Trial
Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial.
N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study
Improvement on blood pressure and skin using roselle drink: A clinical trial
Dipeptide Extract Modulates the Oxi-Antioxidant Response to Intense Physical Exercise
Randomized Clinical Trial of How Long-Term Glutathione Supplementation Offers Protection from Oxidative Damage and Improves HbA1c in Elderly Type 2 Diabetic Patients.
Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes.
Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial.
The effects of the oral supplementation of L-Cystine associated with reduced L-Glutathione-GSH on human skin pigmentation: a randomized, double-blinded, benchmark- and placebo-controlled clinical trial.
The effects of 3 weeks of oral glutathione supplementation on whole body insulin sensitivity in obese males with and without type 2 diabetes: a randomized trial.
Oral Glutathione and Growth in Cystic Fibrosis: A Multicenter, Randomized, Placebo-controlled, Double-blind Trial.
Impact of Glutathione and Vitamin B-6 in Cirrhosis Patients: A Randomized Controlled Trial and Follow-Up Study.
Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis
The clinical effect of glutathione on skin color and other related skin conditions: A systematic review.
Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function.
Glutathione and its antiaging and antimelanogenic effects.
Glutathione as a skin whitening agent: Facts, myths, evidence and controversies.
Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study.
Glutathione supplementation suppresses muscle fatigue induced by prolonged exercise via improved aerobic metabolism.
Glutathione S-transferase M1 and glutathione S-transferase T1 genotype in chronic pancreatitis: a meta-analysis
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.
The association of glutathione S-transferase polymorphisms in patients with osteosarcoma: evidence from a meta-analysis
Common polymorphic deletion of glutathione S-transferase theta predisposes to acquired aplastic anemia: Independent cohort and meta-analysis of 609 patients
A clinical trial of glutathione supplementation in autism spectrum disorders.
Association of glutathione S-transferase M1 and T1 null polymorphisms with the development of cervical lesions: a meta-analysis
Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study.
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
Glutathione and immune function.
Reduced intravenous glutathione in the treatment of early Parkinson's disease.
Quick Facts
- Class
- Tripeptide Antioxidant
- Tier
- B
- Evidence
- Moderate
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 50PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.